Success or failure in Pharma 3.0 — an ecosystem comprised of established industry members, nontraditional companies, and an increasingly informed data-empowered consumer — will be based on life-sciences companies’ ability to develop innovative, outcomes-focused offerings through structured, systematic, and scalable approaches to business model innovation. The two most prevalent elements that will separate the winners and losers in Pharma 3.0 in the coming year are radical business model experimentation and collaboration. Not only will companies have to jockey for a spot among the usual industry competitors, but nonindustry investors that are getting in the game also pose a threat…
Four Keys to Success in the Pharma 3.0 Era
Nontraditional Partnerships Require Nontraditional Views
R.T. (Terry) Hisey. Vice Chairman, U.S. Industry Leader, Life Sciences Practice, Deloitte LLP, a provider of audit, tax, consulting, and financial advisory services. For more information, visit deloitte.com.
Carolyn Buck Luce. Global Pharmaceutical Sector Leader, Ernst & Young, which helps companies to identify and capitalize on business opportunities. For more information, visit ey.com.
Usama Malik. VP, Worldwide Innovation, Pfizer Inc., a research-based pharmaceutical company. For more information, visit pfizer.com.
Kimberly Park. Partner, Janssen Healthcare Innovation, Johnson & Johnson, a global pharmaceutical, medical devices, and consumer packaged goods manufacturer. For more information, visit jnj.com.
Nagaraja Srivatsan. Senior VP and Head of Life Sciences, North America, Cognizant, which offers information technology, consulting, and business process outsourcing services. For more information, visit cognizant.com.
Ann Walz. CEO, Medisys, which is focused on scientific platform development and message evolution. For more information, visit medisyshealth.com.